Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C6461006: PF-08634404 With or Without Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
2025-523523-21-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of PF-08634404 in urothelial carcinoma (UC) (2 cohorts), sponsored by Pfizer. Primary endpoints: Cohort A: Confirmed Objective Response Rate (ORR) by investigator, Safety: Adverse events and 3 more. Planned start May 2026; status: authorised.
02
Drugs
PF-08634404
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2025-523523-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523523-21-00.